Cite

HARVARD Citation

    Aróstegui, J. et al. (2015). Long-term efficacy and safety of Canakinumab in active Hyper-IgD syndrome (HIDS): results from an open-label study. Pediatric rheumatology online journal. 13 (1), p. 1. [Online]. 
  
Back to record